^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
CMAB 819 (nivolumab biosimilar)
i
Other names: CMAB 819
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Mabpharm Limited
Drug class:
PD1 inhibitor
Related drugs:
24d
Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in R/M HNSCC (clinicaltrials.gov)
P1, N=21, Terminated, Taizhou Mabtech Pharmaceutical Co.,Ltd | Trial completion date: Sep 2024 --> Oct 2023 | Active, not recruiting --> Terminated | Trial primary completion date: May 2024 --> Oct 2023; Difficult to recruit subjects
Trial completion date • Trial termination • Trial primary completion date • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Opdivo (nivolumab) • CMAB 819 (nivolumab biosimilar)
12ms
Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in R/M HNSCC (clinicaltrials.gov)
P1, N=21, Active, not recruiting, Taizhou Mabtech Pharmaceutical Co.,Ltd | Recruiting --> Active, not recruiting | N=164 --> 21 | Trial completion date: Sep 2023 --> Sep 2024 | Trial primary completion date: May 2022 --> May 2024
Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Opdivo (nivolumab) • CMAB 819 (nivolumab biosimilar)
1year
Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in R/M HNSCC (clinicaltrials.gov)
P1, N=164, Recruiting, Taizhou Mabtech Pharmaceutical Co.,Ltd | Trial primary completion date: Sep 2022 --> May 2022
Trial primary completion date • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Opdivo (nivolumab) • CMAB 819 (nivolumab biosimilar)
over3years
Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in R/M HNSCC (clinicaltrials.gov)
P1, N=164, Recruiting, Taizhou Mabtech Pharmaceutical Co.,Ltd
Clinical • New P1 trial
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Opdivo (nivolumab) • CMAB 819 (nivolumab biosimilar)
Share via
